Matches in SemOpenAlex for { <https://semopenalex.org/work/W2897664333> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2897664333 abstract "Mild cognitive impairment (“MCI”) is defined as the “symptomatic pre-dementia stage” on the continuum of cognitive decline. Currently, no medications have proven effective for MCI. Preclinical experiments indicate that NA-831 is an endogenous small molecule that exhibits neuroprotection, neurogenesis, and cognitive protective properties across a range of disease models. NA-831 has been shown to be safe and well tolerated in healthy volunteers. A randomized Phase 2A clinical trial of NA-831 was performed in Alzheimer patients with mild cognitive impairment of vascular origin. Inclusion criteria included: (a) male or female, at 55-80 years of age at screening, (b) Mini-Mental State Exam (MMSE) score ≥20 (primary school) or ≥24 (high school or above) (d) Center for Epidemiological Studies-Depression (CES-D) score <27. A total of 56 Patients were randomly assigned to NA-831 at a daily dosage of 10 mg or matched placebo (1:1) for 24 weeks. The primary outcome measures were the changes in Alzheimer's disease assessment scale-cognitive subscale (ADAS-cog), brief cognitive rating scale (BCRS) and clinician's interview-based impression of change plus caregiver input (CIBIC-plus) after 24 weeks. All patients were monitored for adverse events (AEs). Outcome measures were analyzed for both the intention-to-treat (ITT) population and per protocol population. The effects of NA-831 on Alzheimer patients with mild cognitive impairment were measured as statistically significant reductions in scores on the BCSR, and ADAS-cog scales. Based on the BCRS, the effects of NA-831 were apparent after 8 weeks of treatment (p=0.001), with the significant improvement in the following areas: fatigue, anxiety, irritability, affective lability, disturbance to waking, daytime drowsiness, headache, and nocturnal sleep. NA-831 showed significant improvement with the ADAS-cog score changed 3.21 points (NA-831 change −4.47 vs. placebo −1.26; P = 0.001; ITT). CIBIC-Plus showed (23 [82.1%] vs. 5 [17.9%]) patients improved; P = 0.01; ITT). NA-831 was well-tolerated at high dosage up to 50 mg per day. No adverse effects were reported. Over the 6-month treatment period, NA-831 was effective for improving cognitive and global functioning in patients with mild cognitive impairment. As an endogenous compound, NA-831 is well-tolerated and has excellent safety profile." @default.
- W2897664333 created "2018-10-26" @default.
- W2897664333 creator A5053751468 @default.
- W2897664333 creator A5074095383 @default.
- W2897664333 date "2018-07-01" @default.
- W2897664333 modified "2023-10-16" @default.
- W2897664333 title "P4‐201: A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED PHASE 2A CLINICAL TRIAL OF NA‐831 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT" @default.
- W2897664333 doi "https://doi.org/10.1016/j.jalz.2018.07.022" @default.
- W2897664333 hasPublicationYear "2018" @default.
- W2897664333 type Work @default.
- W2897664333 sameAs 2897664333 @default.
- W2897664333 citedByCount "0" @default.
- W2897664333 crossrefType "journal-article" @default.
- W2897664333 hasAuthorship W2897664333A5053751468 @default.
- W2897664333 hasAuthorship W2897664333A5074095383 @default.
- W2897664333 hasConcept C118552586 @default.
- W2897664333 hasConcept C126322002 @default.
- W2897664333 hasConcept C138496976 @default.
- W2897664333 hasConcept C142724271 @default.
- W2897664333 hasConcept C15744967 @default.
- W2897664333 hasConcept C168563851 @default.
- W2897664333 hasConcept C169900460 @default.
- W2897664333 hasConcept C197934379 @default.
- W2897664333 hasConcept C204787440 @default.
- W2897664333 hasConcept C27081682 @default.
- W2897664333 hasConcept C2779134260 @default.
- W2897664333 hasConcept C2779483572 @default.
- W2897664333 hasConcept C2780906993 @default.
- W2897664333 hasConcept C2908647359 @default.
- W2897664333 hasConcept C2984863031 @default.
- W2897664333 hasConcept C71924100 @default.
- W2897664333 hasConcept C83849319 @default.
- W2897664333 hasConcept C99454951 @default.
- W2897664333 hasConceptScore W2897664333C118552586 @default.
- W2897664333 hasConceptScore W2897664333C126322002 @default.
- W2897664333 hasConceptScore W2897664333C138496976 @default.
- W2897664333 hasConceptScore W2897664333C142724271 @default.
- W2897664333 hasConceptScore W2897664333C15744967 @default.
- W2897664333 hasConceptScore W2897664333C168563851 @default.
- W2897664333 hasConceptScore W2897664333C169900460 @default.
- W2897664333 hasConceptScore W2897664333C197934379 @default.
- W2897664333 hasConceptScore W2897664333C204787440 @default.
- W2897664333 hasConceptScore W2897664333C27081682 @default.
- W2897664333 hasConceptScore W2897664333C2779134260 @default.
- W2897664333 hasConceptScore W2897664333C2779483572 @default.
- W2897664333 hasConceptScore W2897664333C2780906993 @default.
- W2897664333 hasConceptScore W2897664333C2908647359 @default.
- W2897664333 hasConceptScore W2897664333C2984863031 @default.
- W2897664333 hasConceptScore W2897664333C71924100 @default.
- W2897664333 hasConceptScore W2897664333C83849319 @default.
- W2897664333 hasConceptScore W2897664333C99454951 @default.
- W2897664333 hasIssue "7S_Part_29" @default.
- W2897664333 hasLocation W28976643331 @default.
- W2897664333 hasOpenAccess W2897664333 @default.
- W2897664333 hasPrimaryLocation W28976643331 @default.
- W2897664333 hasRelatedWork W182016951 @default.
- W2897664333 hasRelatedWork W2007990932 @default.
- W2897664333 hasRelatedWork W2013354290 @default.
- W2897664333 hasRelatedWork W2047125649 @default.
- W2897664333 hasRelatedWork W2064114605 @default.
- W2897664333 hasRelatedWork W2070165017 @default.
- W2897664333 hasRelatedWork W2077992747 @default.
- W2897664333 hasRelatedWork W2418960833 @default.
- W2897664333 hasRelatedWork W2561267217 @default.
- W2897664333 hasRelatedWork W2550787946 @default.
- W2897664333 hasVolume "14" @default.
- W2897664333 isParatext "false" @default.
- W2897664333 isRetracted "false" @default.
- W2897664333 magId "2897664333" @default.
- W2897664333 workType "article" @default.